139 Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)30587-6/abstract
138 Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger).
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)00739-X/abstract
137 PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.
http://www.nejm.org/doi/full/10.1056/NEJMoa1603702
136 Clinical trial of blood-brain barrier disruption by pulsed ultrasound.
http://stm.sciencemag.org/content/8/343/343re2
135 Toca 511 and Toca FC show promising results in treating recurrent high-grade glioma, and a specific molecular signature correlates with treatment-related survival.
http://stm.sciencemag.org/content/8/341/341ra75.abstract
134 Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)00561-4/abstract
133 Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01317-3/abstract
132 Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
http://www.nejm.org/doi/full/10.1056/NEJMoa1516282
131 Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice.
http://www.pnas.org/content/113/9/E1306.abstract
130 CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1506597
129 Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
http://www.nejm.org/doi/full/10.1056/NEJMoa1513257
128 Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
http://www.nejm.org/doi/full/10.1056/NEJMoa1509388
127 Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01120-4/abstract
126 Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01238-6/abstract
125 Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01037-5/abstract
124 Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01281-7/abstract
123 Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)00817-X/abstract
122 Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease.
http://www.nejm.org/doi/full/10.1056/NEJMoa1506002
121 Substantial contribution of extrinsic risk factors to cancer development.
http://www.nature.com/nature/journal/v529/n7584/full/nature16166.html
120 Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)00986-1/abstract
119 Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)00667-4/abstract
118 Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35).
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01168-X/abstract
117 An endoscope with integrated transparent bioelectronics and theranostic nanoparticles for colon cancer treatment.
http://www.nature.com/ncomms/2015/151130/ncomms10059/full/ncomms10059.html
116 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)00471-7/abstract
115 Sensitivity and specificity of mammography and adjunctive ultrasonography to screen for breast cancer in the Japan Strategic Anti-cancer Randomized Trial (J-START): a randomised controlled trial.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)00774-6/abstract
114 Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.
http://www.nejm.org/doi/full/10.1056/NEJMoa1505237
113 DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1506859
112 A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention.
http://www.nejm.org/doi/full/10.1056/NEJMoa1506197
111 Castration radiosensitizes prostate cancer tissue by impairing DNA double-strand break repair.
http://stm.sciencemag.org/content/7/312/312re11
110 Malignant Transformation of Hymenolepis nana in a Human Host.
http://www.nejm.org/doi/full/10.1056/NEJMoa1505892?query=featured_home
109 Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.
http://www.nejm.org/doi/full/10.1056/NEJMoa1506348
108 Detection of human brain tumor infiltration with quantitative stimulated Raman scattering microscopy.
http://stm.sciencemag.org/content/7/309/309ra163
107 Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)60908-4/abstract
106 Daratumumab monotherapy had a favorable safety profile and encouraging efficacy in patients with heavily pretreated and refractory myeloma.
http://www.nejm.org/doi/full/10.1056/NEJMoa1506348
105 Sparing the region of the salivary gland containing stem cells preserves saliva production after radiotherapy for head and neck cancer.
http://stm.sciencemag.org/content/7/305/305ra147.editor-summary
104 Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma.
http://www.nejm.org/doi/full/10.1056/NEJMoa1504542
103 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1503747
102 Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
http://www.nejm.org/doi/full/10.1056/NEJMoa1502309
101 Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
http://www.nejm.org/doi/full/10.1056/NEJMoa1505654
100 PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
http://www.nejm.org/doi/full/10.1056/NEJMoa1500596
|
